One goal of the current study using the Thy1-APPL1 mice was to determine whether an increase in APPL1 is sufficient to drive the same range of early endosome pathologies in vivo, directly testing whether APPL1 can play a primary role in AD-relevant early endosomal alterations. This evidence concerns the gene APPL1 and Alzheimer disease.